The Life Sciences Division's Navid Malik gives his view on the recent recent deal ImmuPharma PLC (LON:IMM) struck with US speciality drugs group Avion Pharmaceuticals.
Malik reckons its lupus candidate Lupuzor could become a 'US blockbuster' by generating over US$1bn revenues per year.